search
Back to results

Plantar Fasciosis Treatment Using Coblation

Primary Purpose

Plantar Fasciitis

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
ArthroCare TOPAZ™ MicroDebrider™ using Coblation
Surgical Fasciotomy
Sponsored by
ArthroCare Corporation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Plantar Fasciitis focused on measuring plantar fascia, plantar fasciitis, Coblation, fasciotomy, conventional surgical fasciotomy, heel spur, heel pain, aponeurosis, plasma based radiofrequency, angiogenesis

Eligibility Criteria

18 Years - 72 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Diagnosis of plantar fasciitis/fasciosis by all of the following: Tenderness with palpation and local pressure over the medial calcaneal tuberosity on passive dorsiflexion of the foot VAS (Visual Analog Scale) pain score of > 5 points on a scale of 0 to 10, during the first few minutes of walking in the morning Ultrasound or magnetic resonance imaging (MRI) confirming plantar fasciitis/fasciosis Symptoms consistent with plantar fasciitis/fasciosis for at least 6 months as assessed by patient history Pain unresponsive to non-steroidal anti-inflammatory drugs (NSAIDs) and any four of the following conservative treatments: rest, taping, orthotics, shoe modifications, night splinting, casting, physical therapy, or local corticosteroid injections for up to 3 months Must be at least 18 years old and no more than 72 years old Must sign the Institutional Review Board (IRB) approved informed consent form Subject is willing and able to complete required follow-up Exclusion Criteria: Body mass index (BMI) > 40 History or documentation showing type I and type II diabetes mellitus Physical findings and documentation of coagulopathy, infection, tumor or other systemic disease(s) History or documentation showing peripheral vascular disease or autoimmune disease Subject has received NSAIDs (e.g., ibuprofen, naproxen) for treatment of plantar fasciitis/fasciosis 2 weeks prior to treatment by this study Subject has received NSAIDs (e.g. ibuprofen, naproxen) or oral corticosteroids 2 weeks prior to treatment by this study Subject is receiving worker's compensation Subject is currently involved in litigation related to the injury being studied Prior surgical treatment of the plantar fascia(s) to be treated by this study Subject is currently participating in another drug/device study related to the injured plantar fascia Pregnant or pregnant suspected subjects Clinically significant bilateral plantar fasciitis/fasciosis with a VAS pain scale of > 5 bilaterally Subject is not capable of understanding or responding to study questionnaires. Extracorporeal shockwave therapy (ESWT) within 6 months of study treatment

Sites / Locations

  • Weil Foot & Ankle Institute

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

A

2

Arm Description

Percutaneous Fasciotomy

Standard Fasciotomy

Outcomes

Primary Outcome Measures

Pain relief

Secondary Outcome Measures

Compare the number of postoperative complications
Evaluate changes in biomechanical function using Ankle-Hindfoot and Midfoot Scale
Assess function and quality of life by the sf-36 questionnaire

Full Information

First Posted
September 12, 2005
Last Updated
August 25, 2015
Sponsor
ArthroCare Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT00189592
Brief Title
Plantar Fasciosis Treatment Using Coblation
Official Title
Plantar Fasciosis Treatment Using Coblation® Prospective, Double-Blind, Randomized Controlled Study
Study Type
Interventional

2. Study Status

Record Verification Date
August 2015
Overall Recruitment Status
Completed
Study Start Date
August 2005 (undefined)
Primary Completion Date
June 2008 (Actual)
Study Completion Date
June 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ArthroCare Corporation

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the effectiveness of Coblation-based fasciotomy for relieving pain associated with recurring plantar fasciosis and, secondarily, to determine whether there may be additional potential benefits stemming from its use.
Detailed Description
Severe recalcitrant heel pain, resulting from repetitive trauma to the plantar fascia, is a relatively commonly observed phenomenon. Although this condition is frequently referred to as 'heel spurs', plantar fasciitis (acute inflammatory stage) and plantar fasciosis (chronic degeneration) are currently accepted as the more accurate terms. Symptoms most often occur during the first few steps in the morning but may also be effected during intense activity or with prolonged standing. The source of pain symptoms, which are usually perceived as a gradual onset of burning, is located at the origin of the plantar fascia at the calcaneous (heel bone). Risk factors such as low or high arches or over-pronation of the foot, systemic disease, or obesity may exacerbate pain. More than two million Americans receive treatment each year for plantar fasciitis and fasciosis. Conservative treatment options for plantar fasciosis include rest, stretching, strengthening, and massage, progressing to non-steroidal anti-inflammatories, steroid injections or iontophoresis with continued recalcitrance. Orthotics, heel cups, night splints and plantar strapping are other conservative options frequently recommended by treating physicians. Patient outcomes and response to conservative measures are usually positive, with non-responsive cases, approximately 10% of all presenting cases, receiving surgical care. Extracorporeal shockwave treatment has recently been advocated for the recalcitrant cases and has shown to be effective in 60-80 percent of the cases. Plantar fascia release, either partial or complete, is commonly the surgical procedure of choice for treating plantar fasciosis. However, this surgery has a risk of complications and is thought to alter the biomechanics of the foot, which may be linked to post-operative lateral column pain and long-term disability. Because of the potential postoperative sequelae with plantar fascia release, it is valuable to examine less invasive surgical techniques for treating recalcitrant plantar fasciosis. The concept of using a plasma RF-based microsurgical approach as a viable modality for treating tendinosis, and now, recalcitrant plantar fasciosis, was originally drawn from the research work conducted in patients treated for congestive heart failure using laser or RF-based transmyocardial revascularization (TMR). The mechanism of action behind the clinical success observed with laser and RF-based TMR was theorized to be associated with the localized angiogenic healing response noted to occur following the procedure. Localized angiogenesis had not been observed previously using mechanical devices for TMR, which were also less successful clinically. To substantiate adopting a TMR-like approach for treating tendinosis, the capability of plasma RF-based microsurgery for initiating an angiogenic healing response was examined in vivo using histology and biochemical analysis. The sum of several studies provides good evidence to suggest that plasma RF-based microsurgery can promote an angiogenic healing response using an appropriate application. Preliminary clinical experience following plasma RF-based micro-tenotomy has demonstrated excellent success in treating chronic, refractive tendinosis. The investigators reported that this technique was technically simple to perform and was much less invasive than conventional surgery. Patients had a rapid and uncomplicated recovery and reported minimal to no pain 7-10 days following the procedure; their pain relief persisted or improved through 24 months. Magnetic resonance imaging correlated well with clinical results. These promising clinical findings, as well as the evidence from the basic research studies, led us to consider evaluating this plasma RF-based approach for treating symptomatic, chronic, recalcitrant heel pain resembling plantar fasciosis. The purpose of this study is to evaluate the effectiveness of Coblation-based fasciotomy for relieving pain associated with recalcitrant plantar fasciosis and, secondarily, to determine whether there may be additional potential benefits stemming from its use, such as reduced incidence of postoperative complications and improved function, compared to conventional surgery.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Plantar Fasciitis
Keywords
plantar fascia, plantar fasciitis, Coblation, fasciotomy, conventional surgical fasciotomy, heel spur, heel pain, aponeurosis, plasma based radiofrequency, angiogenesis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
45 (Actual)

8. Arms, Groups, and Interventions

Arm Title
A
Arm Type
Experimental
Arm Description
Percutaneous Fasciotomy
Arm Title
2
Arm Type
Active Comparator
Arm Description
Standard Fasciotomy
Intervention Type
Device
Intervention Name(s)
ArthroCare TOPAZ™ MicroDebrider™ using Coblation
Intervention Description
Percutaneous treatment of plantar fascia using the Topaz device. No incision performed.
Intervention Type
Procedure
Intervention Name(s)
Surgical Fasciotomy
Intervention Description
Standard surgical fasciotomy using an incision to treat the plantar fascia.
Primary Outcome Measure Information:
Title
Pain relief
Time Frame
at 24 hours, 48 hours, 7 to 14 days, 4 to 6 weeks, 3 months, 6 months, 12 months
Secondary Outcome Measure Information:
Title
Compare the number of postoperative complications
Time Frame
When and if they occur
Title
Evaluate changes in biomechanical function using Ankle-Hindfoot and Midfoot Scale
Time Frame
4 to 6 weeks, 3 months, 6 months and 1 year
Title
Assess function and quality of life by the sf-36 questionnaire
Time Frame
at 4 to 6 weeks, 3 months, 6 months, 1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
72 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of plantar fasciitis/fasciosis by all of the following: Tenderness with palpation and local pressure over the medial calcaneal tuberosity on passive dorsiflexion of the foot VAS (Visual Analog Scale) pain score of > 5 points on a scale of 0 to 10, during the first few minutes of walking in the morning Ultrasound or magnetic resonance imaging (MRI) confirming plantar fasciitis/fasciosis Symptoms consistent with plantar fasciitis/fasciosis for at least 6 months as assessed by patient history Pain unresponsive to non-steroidal anti-inflammatory drugs (NSAIDs) and any four of the following conservative treatments: rest, taping, orthotics, shoe modifications, night splinting, casting, physical therapy, or local corticosteroid injections for up to 3 months Must be at least 18 years old and no more than 72 years old Must sign the Institutional Review Board (IRB) approved informed consent form Subject is willing and able to complete required follow-up Exclusion Criteria: Body mass index (BMI) > 40 History or documentation showing type I and type II diabetes mellitus Physical findings and documentation of coagulopathy, infection, tumor or other systemic disease(s) History or documentation showing peripheral vascular disease or autoimmune disease Subject has received NSAIDs (e.g., ibuprofen, naproxen) for treatment of plantar fasciitis/fasciosis 2 weeks prior to treatment by this study Subject has received NSAIDs (e.g. ibuprofen, naproxen) or oral corticosteroids 2 weeks prior to treatment by this study Subject is receiving worker's compensation Subject is currently involved in litigation related to the injury being studied Prior surgical treatment of the plantar fascia(s) to be treated by this study Subject is currently participating in another drug/device study related to the injured plantar fascia Pregnant or pregnant suspected subjects Clinically significant bilateral plantar fasciitis/fasciosis with a VAS pain scale of > 5 bilaterally Subject is not capable of understanding or responding to study questionnaires. Extracorporeal shockwave therapy (ESWT) within 6 months of study treatment
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lowell S. Weil, Sr., DPM
Organizational Affiliation
Weil Foot & Ankle Institute
Official's Role
Principal Investigator
Facility Information:
Facility Name
Weil Foot & Ankle Institute
City
Des Plaines
State/Province
Illinois
ZIP/Postal Code
60016
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Plantar Fasciosis Treatment Using Coblation

We'll reach out to this number within 24 hrs